Ramucirumab is a recombinant human IgG1 monoclonal antibody that binds to VEGFR-2 and blocks VEGF-A-stimulated endothelial cell proliferation and migration, hence down-regulating tumor vascularity and growth [40]. This evidence concerns the gene VEGFA and neoplasm.